Denali Therapeutics has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million. The PRV was awarded after FDA approval of AVLAYAH™, the first biologic designed to cross the blood-brain barrier for treating Hunter syndrome. Proceeds will support Denali's clinical pipeline targeting lysosomal storage disorders and neurodegenerative diseases like Alzheimer's and Parkinson's. This sale strengthens Denali's financial position to advance its innovative TransportVehicle™ platform therapies.
Allegro MicroSystems appointed Brian C. White as an independent director on its Board, effective June 17, 2026. White brings over 30 years of experience in semiconductor leadership and financial strategy, having served as CFO for several public semic...
Citadel Securities warns that the Federal Reserve's decision to pause rate hikes in June is only temporary. They highlight that ongoing supply shocks, a strong labor market, and a large AI investment cycle are driving persistent inflation, which will...
Chicago Atlantic Real Estate Finance, Inc. (REFI) and Chicago Atlantic BDC, Inc. (LIEN) have agreed to merge, with REFI electing to become a business development company (BDC) and merging into LIEN in an all-stock deal. The combined company will oper...
Scorpio Tankers Inc. announced updated daily Time Charter Equivalent (TCE) rates for Q2 2026, reflecting their fleet's contracted voyages and time charters. The company expects diluted shares outstanding between 53 to 54 million for the quarter, fact...
New research from Wood Mackenzie reveals that the metals demand for data centers extends far beyond servers to include extensive power infrastructure like grid upgrades, transmission lines, and on-site power generation. This broader view shows alumin...
